Progeny 3 Inc. Makes New Investment in Cellebrite DI Ltd. $CLBT

Progeny 3 Inc. bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the 1st quarter, Holdings Channel reports. The firm bought 1,128,129 shares of the company’s stock, valued at approximately $15,546,000. Cellebrite DI makes up 0.8% of Progeny 3 Inc.’s investment portfolio, making the stock its 27th biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the period. Advisory Services Network LLC purchased a new position in Cellebrite DI during the third quarter valued at approximately $40,000. CWM LLC increased its holdings in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. First Horizon Corp raised its stake in Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares in the last quarter. Finally, Vestcor Inc purchased a new stake in Cellebrite DI during the third quarter worth $70,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLBT. DA Davidson initiated coverage on Cellebrite DI in a report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC decreased their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Price Performance

NASDAQ:CLBT opened at $14.22 on Monday. The stock has a market capitalization of $3.55 billion, a price-to-earnings ratio of 50.79, a PEG ratio of 1.76 and a beta of 1.17. Cellebrite DI Ltd. has a 52 week low of $11.02 and a 52 week high of $19.98. The firm has a 50 day moving average of $14.19 and a 200 day moving average of $14.28.

Insider Activity

In other news, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the sale, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 158,191 shares of company stock worth $2,479,438. Insiders own 5.70% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.